trials testing new molecules, new indications and new combinations are in progress, including in gynecological cancers, including ovarian cancer. Compared to the benefits expected based on preclinical models, patient benefits in term of long-term survival, however, remained modest. Recent experimental results have demonstrated that tumors treated with anti-angiogenic therapies, contrary to initial assumptions, can develop evasive resistance and rapidly progress to become invasive and metastatic. Thus, in spite of the undisputed success of this new therapeutic approach some old questions on tumor angiogenesis have remained unanswered and new ones have emerged. They include the understanding about how anti-angiogenic therapy and chemotherapy synergize, the characterization of the biological consequences of sustained suppression of angiogenesis on tumor biology and normal tissue homeostasis, and the mechanisms of tumor escape from anti-angiogenesis. Bone marrow-derived and tumor-mobilized cells recruited at tumor sites are emerging as critical determinant of resistance to anti-angiogenic therapy and may represent novel therapeutic targets. Furthermore, although it has been suggested that biomarkers of angiogenesis would greatly facilitate the clinical development of anti-angiogenic therapies, so far there are no validated biomarkers of angiogenesis and surrogate biomarkers of anti-angiogenesis. In order to improve the clinical use of available anti-angiogenic drugs and the development of new ones it will be important to challenge some of the basic concepts of tumor angiogenesis biology and the relationship between tumor vessels and tumor cells. In this lecture I will review some of the emerging critical issues in tumor angiogenesis and discuss their impact on the development of anti-angiogenic therapies.

195 INVITED

Clinical experience with antiangiogenic targeting in ovarian cancer

M.A. Bookman[1]. [1]*Fox Chase Cancer Center, Medical Oncology, Philadelphia, USA*

The biology of Vascular Permeability Factor (VPF) was first described in 1983, followed by the demonstration of constitutive expression in ovarian cancer in 1994. This led to efforts at antibody targeting in tumor model systems, with promising control of ascites and tumor growth. VPF is now recognized as Vascular Endothelial Growth Factor (VEGF), and our knowledge of VEGF expression, receptor biology, and signal transduction has expanded considerably over the last 10 years, culminating in successful targeting strategies through ligand sequestration, inhibition of receptor activation, interference with internal signaling pathways, and gene expression. In addition, a variety of other factors have been identified that contribute to a regulatory network of tumor-associated angiogenesis, introducing an array of potential targets and combinations.

The most well-studied agent has been bevacizumab, a monoclonal antibody that sequesters VEGF, as well as aflibercept, an antibody-like protein constructed of VEGF binding domains. Although single-agent activity with bevacizumab in lung, colorectal, and breast cancer was limited, phase III trials in combination with chemotherapy have demonstrated modest improvements in long-term clinical outcomes. Interest in ovarian cancer was accelerated based on phase II trials demonstrating a 20% RECIST response rate in patients with recurrent disease, together with control of ascites. While generally well-tolerated with a predictable toxicity profile, there was initial concern regarding the risk of bowel perforation that appears largely related to patient selection criteria. As a result, single-agent phase II trials were rapidly followed by 2 front-line phase III trials (in combination with chemotherapy) coordinated by GOG-US and MRC-UK. Accrual has been completed on both studies, and results are pending.

Inhibitors of VEGF-associated tryosine kinase (TKI) have also been evaluated in phase II trials, including sorafinib, cediranib, and pazopanib, and phase III studies of maintenance or consolidation have been initiated, with additional plans for front-line trials. Combinations of bevacizumab with TKI appear to have a high response rate, but at the expense of increased serious toxicity, and more studies with newer agents are needed. There are also limited data emerging with regard to other network components involved in tumor angiogenesis, such as angiopoietin-2, protein kinase-cβ, AKT, mTOR, or regulation of HIF1α activity.

Many questions remain with regard to the optimal clinical strategy for incorporation of these agents, including timing (front-line, maintenance, or recurrence), as well as combinations with cytotoxic chemotherapy or other molecular-targeted agents. In addition, there are not yet any comparative data to guide selection of the best agents, or class of agents, for future study.

Finally, the mechanism of action in ovarian cancer remains to be elucidated. Are these agents acting on tumor-associated vessels to normalize blood flow and reduce capillary permeability (as originally proposed), or are they acting directly on tumor cells, or perhaps accelerating the immune response through maturation of dendritic cells? Clearly, more randomized phase II trials with comparative and translational endpoints are needed to guide future investigations.

196 INVITED

Emerging new targets in ovarian cancer

S. Kaye[1]. [1]*Royal Marsden Hospital, Medicine, Sutton, United Kingdom*

In the era of molecular targeted therapy, ovarian cancer provides a particularly exciting opportunity for clinical new drug testing, in which pathway-specific agents are being linked to predictive biomarkers aimed at identifying patients most likely to benefit. The paradigm is the remarkable activity of single agent PARP inhibitor therapy for patients with BRCA 1/2 mutation positive ovarian cancer. This is based on the exquisite sensitivity of cancer cells which are deficient in the ability to repair DNA damage through homologous recombination (HR); the challenge for the future is to assess this new form of treatment in that larger group of ovarian cancer patients, with sporadic disease, who are also likely to have HR deficiency. We already have preliminary evidence to indicate that efficacy in these patients is possible.

Another pathway likely to provide a rich seam of novel agents is the PI3 kinase/AKT/mTOR pathway, since amplifications and mutations are well recognised in ovarian cancer. A number of agents are already in the clinic; here it is likely that a combination strategy will ultimately be employed, aimed at dealing with cytotoxic drug resistance through modulation of this pathway. Similarly, potent inhibitors of other relevant targets such as the SRC oncogene hold particular promise, based on molecular analysis of clinical material indicating the likely relevance of this target in ovarian cancer.

A key aim for the future is the identification of novel targets in so-called 'stem cells', which are increasingly being identified in ovarian cancer patients. These may include novel pathways such as the sonic hedgehog pathway, as well as well-recognised transport proteins (from the ABC transporter family) which may play a particular role in stem cell biology.

197 INVITED

Molecular determinants of acquired resistance

S. De Jong[1]. [1]*Groningen University Hospital, Groningen, The Netherlands*

Resistance to platinum-based chemotherapy is a major problem in the treatment of ovarian cancer. The reduced tendency of ovarian cancer cells to undergo apoptosis contributes to drug resistance. In order to gain more insight in the molecular mechanisms underlying platinum resistance, we profiled 9 paired stage III/IV serous ovarian cancer specimens obtained before and after platinum-based chemotherapy using oligonucleotide microarrays. The prognostic value of differentially expressed genes and deregulated biological pathways was assessed in an independent set of 157 previously profiled late stage serous ovarian cancers. Immunohistochemical staining of MB1 as representative for proteasome pathways confirmed the prognostic value of these pathways at the protein level. Our analyses reveal both well-known as well as novel genes and pathways tentatively involved in platinum resistance, including the insulin-like growth factor (IGF)-axis. High IGF-1 receptor (IGF-1R) and insulin receptor (IR) expression were observed in 51.1% and 19.9% of ovarian cancers, respectively. In univariate analysis for stage III/IV ovarian cancers, high IGF-1R expression was related to improved prognosis. In contrast, high IR expression was independently associated with poor disease specific survival (HR 2.0, 95%CI 1.30−3.09). Almost all cancers expressed IGF-I (100%), IGF-II (100%), IGF-1R (73.3%) and both IR-A and IR-B isoforms (94.4%) but none insulin mRNA. IGF-II levels in cyst fluid were elevated compared to cystadenomas suggesting a possible autocrine/paracrine activation of the IGF-axis. We investigated whether the IR inhibitor hydroxy-2-naphthalenylmethylphosphonic acid (HNMPA) treatment could sensitize the cisplatin-sensitive ovarian cancer cell line A2780 and its cisplatin-resistant subline C30 to cisplatin-induced apoptosis. A2780 and C30 showed membrane expression of IGF-1R and IR. Addition of IGF-I, IGF-II or insulin resulted in activation of the IGF-1R/IR signaling in A2780 and C30. A combination of HNMPA and cisplatin strongly enhanced apoptosis and decreased survival in both cell lines, indicating that inhibition of pro-survival signaling enhances cisplatin-induced apoptosis. Another strategy for targeting ovarian cancer involves shifting cellular balance in favor of cell death via activation of the intrinsic (mitochondrial) and extrinsic apoptotic pathway. In cisplatin resistant ovarian cancer cells we found reduced activation of p53 and reduced apoptosis-induction by recombinant human form of the death ligand TNF related apoptosis inducing ligand (rhTRAIL). Combination of cisplatin and rhTRAIL enhanced apoptosis in A2780 and a cisplatin resistant subline. Both rhTRAIL and rhTRAIL-DR5, a rhTRAIL variant that specifically binds to pro-apoptotic DR5 receptor induced high levels of apoptosis in combination with cisplatin with rhTRAIL-DR5 being most potent. Anti-tumor efficacy of rhTRAIL-DR5 or rhTRAIL in combination with cisplatin was determined in an intraperitoneal growing bioluminescent A2780 xenograft model. Intraperitoneal administration of rhTRAIL or rhTRAIL-DR5 plus cisplatin resulted in 85% ($p = 0.003$) and

97% (p = 0.002) reduction, as compared to A2780 tumor progression in vehicle treated animals, indicating that targeting both the intrinsic and extrinsic apoptosis pathway can be a new strategy for more effective ovarian cancer treatment.

Scientific Symposium (Wed, 23 Sep, 09:00−11:00)
Divergence within cancer nursing roles

198 INVITED

Revision of professional roles: is this safe and effective?

M.G.H. Laurant[1], M. Harmsen[1], H. Wollersheim[1], R.P.T.M. Grol[1], M.J. Faber[1], B. Sibbald[2]. [1]*Radboud University Nijmegen Medical Centre, Scientific Institute for Quality of Healthcare, Nijmegen, The Netherlands;* [2]*University of Manchester, National Primary Care Research and Development Centre, Manchester, United Kingdom*

Background: Pressures to increase the quality of care and reduce the cost of healthcare services have led to the redefinition of the roles of healthcare professionals. There has been an upsurge in the number and types of healthcare professionals working alongside physicians. Here we are concerned with a subset of revisions in which advanced practice nurses (i.e. nurse practitioners, specialist nurse or nurse clinicians, etc.) take on defined tasks that were previously the exclusive domain of physicians. There are two conceptually different approaches to role revision in this context. The first is to deploy nurses as supplements for physicians. Nurses working in this way provide additional services which are intended to complement or extend those provided by physicians. The second approach is to deploy nurses as substitutes for physicians. Nurses working in this way provide the same services as physicians.
Objective: To determine the (cost-) effectiveness of advanced practice nurses working as physicians' supplements or substitutes?
Method: We conducted a systematic literature review of literature reviews.
Results: Eighteen systematic reviews of role revision between physicians and advanced practice nurses were included. Six reviews studied the impact of role revision in primary healthcare settings such as general practice/family medicine, ambulatory or outpatient care, and community care; five reviews focused on secondary healthcare settings such as hospitals and accident and emergency departments; two reviews focused on home care; and the remainder included research in both primary healthcare and secondary healthcare settings. The clinical domain in which the nurses worked varied from generalist care, undifferentiated care or care for multiple diseases to specialist care. None of the reviews was focused on patients with cancer. Eight reviews studied the effects of substitution, eight reviews studied the effects on supplementation and two reviews concerned a mixture of both substitution and supplementation.
The findings showed that patients are equally or better satisfied with the care provided by nurses and clinical outcomes for patients may have improved. Metabolic control of parameters (e.g. HbA1c) sometimes improved by nurses provided care, and mortality rates were not different compared to physicians. In terms of care processes, findings suggest that nurses more frequently provide advice and information to patients and can improve access to healthcare services and treatments. The volume of resources used was larger with nurse-led care than physician-led care. In particular, nurses seemed to order more tests and investigations. In primary care, the length of nurses' consultations was significantly longer than that of physicians. The overall effects on the costs of healthcare and cost-effectiveness were inconclusive.
Conclusion: The available evidence suggests that role revision between physicians and advance practice nurses is a viable strategy; it does not jeopardize patient care and may sometimes improve its quality. However, cost-savings are not always evident and may depend on the specific context of care.

199 INVITED

Evidence of value-added benefit of specialist nursing roles?

D. Doran[1]. [1]*Lawrence Bloomberg Faculty of Nursing -, Nursing, Toronto, Canada*

Background: All practitioners in the health care field are being challenged to find ways to demonstrate that the care they provide leads to improvement in outcomes for patients. To accomplish that, practitioners are attempting to identify the relevant outcomes that can be linked in a meaningful way to their own practices.
Purpose: This paper will review the most recent accumulated evidence related to patient and system outcomes that are associated with the role of the clinical nurse specialist (CNS) (advanced practice) role. The objectives include: (1) to identify the essential characteristics or attributes defining CNS practice; (2) to identify outcomes associated with the CNS role; and (3) to determine the extent to which each outcome has demonstrated sensitivity to the CNS role.
Methodology: A systematic review of the literature was conducted. Evidence for the following nurse-sensitive outcomes was reviewed: clinical, functional status, health care utilization, satisfaction, and system. Each study was reviewed using the following framework: research design, setting for practice, sample, method of accounting for confounding variables that could influence the results, CNS role activities, intervention tested, and research results.
Results: The systematic review of the literature showed that the contribution of the CNS role to patient outcomes is variable and of a small magnitude. CNSs contribute to disease/condition specific outcomes, physical and psychosocial symptom outcomes, early identification and prevention of complications, self-management, and patient satisfaction. At the system level CNSs contribute to reduced health care costs, reduced hospitalizations, and reduced hospital length of stay.
Conclusion: Future research is needed to confirm some of the outcome indicators for which there is mixed evidence of sensitivity to CNS practice.

200 INVITED

Developing the potential of community cancer nursing?

C. Kennedy[1]. [1]*Edinburgh Napier University, School of Nursing Midwifery and Social Care, Edinburgh, United Kingdom*

The aim of this presentation is to consider the challenges and opportunities facing nurses who support people with cancer and their families in the community. I propose that 'one size' cannot fit all and innovative approaches to care provision are required to ensure the needs of people and families affected by cancer are met.
In this presentation I will explore the potential contribution of nurses through the cancer trajectory. The focus will be on the exploration of how the needs of people affected by cancer can be met by specialist and generalist community nurses and the interface between primary and secondary care. The following questions form the basis of the presentation:

- What are the challenges and drivers in providing nursing support in the community for those affected by cancer?
- What do we know about the roles currently carried out by nurses in the community?
- What do people affected by cancer want/expect/need services to provide?
- How can nurses develop approaches to care delivery that can meet identified needs across the cancer trajectory from prevention to palliative care?

Countries across Europe face similar challenges in healthcare as the incidence of cancer and an ageing population increases. Furthermore, rising degenerative or chronic diseases, rapid technological developments and the need to change the emphasis from acute care to community care are impacting on service delivery. A primary focus on reducing acute care through emergency admissions and improving health and well-being through preventive care, support for self-care, targeting those at risk, and pro-active approaches in the form of anticipatory care are also emerging as important factors in health care. Nurses are, and need to be, at the forefront of new models for service delivery.
Advances in diagnostic techniques and the treatment of cancer mean more people are surviving cancer. A consequence of improved treatments means some people experience long term physical and psychosocial problems.
Given the complex nature of the cancer trajectory and care aims focused around prevention, self care, rehabilitation and survivorship through to palliative care the potential for gaps and unmet needs is considerable. It is unlikely that specialist cancer nurses can deal with this burgeoning workload therefore generalist nurses will be important in service models.
This presentation will draw on policy and research and propose a model which is patient centred. The potential of specialist and generalist cancer nursing roles to meet needs throughout the trajectory will be identified. The intention is not to polarise the debate but rather to map out a possible service model to stimulate debate and discussion.

201 INVITED

Workforce planning in developing specialist cancer nursing roles

P. Trevatt[1]. [1]*North East London Cancer Network, The Royal London Hospital, London, United Kingdom*

Introduction: In the UK the number of Cancer Nurse Specialists has grown dramatically in recent years. However, in the absence of any workforce strategy this increase has been predominately reactive and uncoordinated. Quantitative data on the UK cancer specialist workforce remains weak and without accurate data it is impossible to effectively commission or develop future specialist nursing roles that will meet projected service needs.